The involvement of glutamate in the pathophysiology of depression.
In spite of more than 40 years of thorough studies, conventional antidepressants still have many limitations that hinder the effective treatment of depression. It seems that a breakthrough in the therapy of depression will require going beyond a monoamine-based theory of depression. Converging lines of evidence indicate that the glutamatergic system might be a promising target for a novel antidepressant therapy. Both ionotropic glutamate receptor ligands (functional NMDA receptor antagonists and AMPA receptor potentiators) and compounds acting at metabotropic glutamate receptors (mGluRs; group I mGluR antagonists, group II antagonists and group III agonists) produce antidepressant-like activity in several preclinical and some clinical studies. In this review, current knowledge and crucial hypotheses concerning the role of glutamate in the pathophysiology of depression are discussed.
Palucha
A
A
Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland. nfpaluch@cyf-kr.edu.pl
Pilc
A
A
D000928:Antidepressive Agents / Q000494:pharmacology; D019208:Brain-Derived Neurotrophic Factor / Q000502:physiology; D003863:Depression / Q000188:drug therapy / Q000209:etiology*; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D006801:Humans; D018094:Receptors, Metabotropic Glutamate / Q000187:drug effects / Q000502:physiology*; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors / Q000502:physiology*
D000928:Antidepressive Agents; D019208:Brain-Derived Neurotrophic Factor; D018691:Excitatory Amino Acid Antagonists; D018094:Receptors, Metabotropic Glutamate; D016194:Receptors, N-Methyl-D-Aspartate